Location History:
- Leiderdorp, NL (2001 - 2008)
- Leiden, NL (2008 - 2010)
Company Filing History:
Years Active: 2001-2010
Title: The Innovative Contributions of Mathieu Hubertus Maria Noteborn
Introduction
Mathieu Hubertus Maria Noteborn is a notable inventor based in Leiderdorp, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the area of apoptosis and viral vaccines. With a total of six patents to his name, Noteborn's work has opened new avenues for therapeutic possibilities.
Latest Patents
One of Noteborn's latest patents involves apoptin-associating proteins. This invention relates to apoptosis and provides novel therapeutic possibilities, including combinatorial therapies and therapeutic compounds that can work alone or in conjunction with apoptin, especially in cases where p53 is partially non-functional. Another significant patent focuses on chicken anemia virus mutants and vaccines. This invention utilizes coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) inserted into a baculovirus vector and expressed in insect cells. The results showed that only lysates of insect cells synthesizing equivalent amounts of all three recombinant CAV proteins induced neutralizing antibodies in inoculated chickens, providing protection against clinical disease after CAV challenge.
Career Highlights
Mathieu Noteborn is currently associated with Leadd B.V., where he continues to innovate and contribute to the field of biotechnology. His work has been instrumental in developing vaccines and therapeutic strategies that address significant health challenges.
Collaborations
Noteborn has collaborated with several professionals in his field, including Astrid Adriana Anna Maria Danen-Van Oorschot and Guus Koch. These collaborations have further enhanced the impact of his research and inventions.
Conclusion
Mathieu Hubertus Maria Noteborn's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His innovative work continues to pave the way for advancements in therapeutic solutions and vaccine development.